英諾激光(301021.SZ):公司的激光器產品譜系齊全
格隆匯12月6日丨英諾激光(301021.SZ)近期在接待機構投資者調研時表示,激光器是激光設備的核心部件,公司由激光器業務起步,在固體和超快激光器領域取得領先的行業地位;公司的激光器產品譜系齊全,是全球少數同時具有納秒、亞納秒、皮秒、飛秒激光器的供應商之一,是全球少數實現工業深紫外激光器批量交付的供應商之一;在拓展專用設備領域時,公司可以從激光器、光學系統到運動控制系統進行深度定製,實現最優的綜合性能。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.